Discovery Laboratories Inc (DSCO)

1.77
0.03 1.61
NASDAQ : Health Care
Prev Close 1.80
Open 1.82
Day Low/High 1.70 / 1.82
52 Wk Low/High 1.42 / 8.12
Volume 12.44K
Avg Volume 94.60K
Exchange NASDAQ
Shares Outstanding 8.19M
Market Cap 31.62M
EPS -7.25
P/E Ratio N/A
Div & Yield N.A. (N.A)
Biotech Stock Mailbag: Cyclacel Fallout, the Skinny on Vivus, Celldex's Crash

Biotech Stock Mailbag: Cyclacel Fallout, the Skinny on Vivus, Celldex's Crash

Biotech columnist Adam Feuerstein answers readers' questions about health-care companies.

These Drugs Stocks Will Win FDA Approval

These Drugs Stocks Will Win FDA Approval

Contestants in TheStreet's FDA Drug-Approval Contest forecast their winners and losers.

Play TheStreet's FDA Drug-Approval Contest

Play TheStreet's FDA Drug-Approval Contest

The FDA will issue approval decisions on 17 drugs over the next four months. How well can you predict which drugs will be approved or rejected?

27 Hot Drugs Facing FDA Approval in 2012

27 Hot Drugs Facing FDA Approval in 2012

These are the biotech and drug stocks facing key FDA drug approval decisions in 2012.

22 Hot Drugs Facing FDA Approval in 2012

22 Hot Drugs Facing FDA Approval in 2012

These are the biotech and drug stocks facing key FDA drug approval decisions in 2012.

Biotech Stock Mailbag: Mela Sciences

Biotech Stock Mailbag: Mela Sciences

Biotech columnist Adam Feuerstein answers readers' questions and concerns about health care and drug-related stocks.

OXiGene: Small-Cap Winners

OXiGene: Small-Cap Winners

TheStreet presents a rundown of the winners in the small-cap space during the day's trading.

Discovery Labs Provides Expanded Update Regarding Its Program For Surfaxin(R) U.S. Marketing Authorization

Discovery Labs Provides Expanded Update Regarding Its Program For Surfaxin(R) U.S. Marketing Authorization

Company to Hold Conference Call to Detail Progress Towards Surfaxin Complete Response

Biotech Stock Mailbag: Orexigen Therapeutics

Biotech Stock Mailbag: Orexigen Therapeutics

Biotech columnist Adam Feuerstein answers readers' questions and concerns about health care and drug-related stocks.

15 Biotech Stock Predictions for 2011

15 Biotech Stock Predictions for 2011

Adam Feuerstein peers into his crystal ball to offer somewhat improbable yet highly surprising biotech stock predictions for the coming year.

Discovery Labs Receives Nasdaq Delisting Notification Related To Minimum Bid Price And Plans To File Request For Hearing

Discovery Labs Receives Nasdaq Delisting Notification Related To Minimum Bid Price And Plans To File Request For Hearing

Company Proposal at Annual Meeting of Stockholders Supports Plan for Potential Continued Listing on The NASDAQ Capital Market(R)

Discovery Labs Appoints W. Thomas Amick As Chief Executive Officer

Company Leadership Solidified With Respected Biopharmaceutical Industry Veteran